Crohn's disease: FC useful for detecting small bowel inflammation

  • Iwamoto F & al.
  • J Gastroenterol Hepatol
  • 11 Jun 2018

  • curated by Miriam Davis, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Fecal calprotectin (FC) levels accurately predict Crohn's disease activity in both large and small bowel when evaluated against balloon-assisted endoscopy (BAE).

Why this matters

  • FC is less invasive and less expensive than BAE.

Study design

  • Multicenter, cross-sectional observational study of 69 patients with Crohn's disease, 39 of whom had small bowel disease only.
  • FC levels were compared with disease activity, as measured by BAE.
  • Disease activity with BAE was measured by the extended simplified endoscopic activity score for Crohn's disease (eSES-CD).
  • Funding: Thermo Fisher Scientific.

Key results

  • Across all patients, FC levels correlated with the eSES-CD measured by BAE (r, 0.663; P<.001>
  • In patients with only small bowel disease, FC levels also correlated with the eSES-CD (r, 0.607; P<.001>
  • By receiver operating characteristic analysis, the optimal cutoff of FC for predicting mucosal healing across all patients was 92 mg/kg:
    • sensitivity, 94%;
    • specificity, 88%;
    • positive predictive value (PPV), 98%;
    • negative predictive value (NPV), 64%;
    • area under the curve (AUC), 0.91.
  • The optimal cutoff was also 92 mg/kg for patients with only small bowel disease:
    • sensitivity, 87%;
    • specificity, 88%;
    • PPV, 96%;
    • NPV, 64%;
    • AUC, 0.85.

Limitations

  • Small number of subjects.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit